NCT02457793View on ClinicalTrials.gov

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 16, 2015

Primary Completion Date

December 5, 2016

Study Completion Date

December 5, 2016

Conditions
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
Interventions
DRUG

Cobimetinib

Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.

DRUG

GDC-0994

GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.

Trial Locations (5)

37203

Sarah Cannon Research Institute, Nashville

63110

Washington University School of Medicine, St Louis

80045-2517

University of Colorado, Aurora

06520

Yale Cancer Center, New Haven

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT02457793 - A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter